Blurbs

Universal Health (UHS) Gets a Buy Rating from Mizuho Securities

Mizuho Securities analyst Ann Hynes reiterated a Buy rating on Universal Health (UHSResearch Report) on July 26 and set a price target of $121.00. The company’s shares closed last Thursday at $111.78.

According to TipRanks.com, Hynes is a 5-star analyst with an average return of 9.3% and a 59.9% success rate. Hynes covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, AmerisourceBergen, and Quest Diagnostics.

Currently, the analyst consensus on Universal Health is a Hold with an average price target of $116.38, representing a 6.5% upside. In a report issued on July 19, Wolfe Research also maintained a Buy rating on the stock with a $111.00 price target.

See the top stocks recommended by analysts >>

Based on Universal Health’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $3.32 billion and net profit of $164 million. In comparison, last year the company earned revenue of $3.2 billion and had a net profit of $325 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Universal Health Services, Inc. operates as a healthcare management company, which through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. It operates through the following segments: Acute Care Hospital Services, Behavioral Health Care Services, and Other. The Other segment consists of centralized services such as information technology, purchasing, reimbursement, accounting and finance, taxation, legal, advertising, and design and construction. The company was founded by Alan B. Miller in 1979 and is headquartered in King of Prussia, PA.

Read More on UHS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos